Skip to content
AnalystLens

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed October 22, 2024
Period End
September 30, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-Q filed October 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported strong third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024.

Total revenue was $533.3 milliona for the three months ended September 30, 2024, up from $492.5 million a year earlier, and $1.57 billion for the nine months, up from $1.39 billion. Income from operations rose to $112.3 million for the quarter from $84.9 million, and net income was $96.4 million, or $3.01 per diluted share, compared with $70.6 million, or $2.22 per diluted share, in the prior-year quarter. The filing states that growth was driven primarily by the Metabolic, Oncology and Cardiology therapeutic areas.

Backlog reached $2,927.4 millionb as of September 30, 2024, up from $2,689.5 million a year earlier, and net new business awards were $533.7 million for the quarter and $1,700.3 million for the nine months. The company expects roughly $1,610.0 million to $1,630.0 million of backlog to convert to net revenue over the next twelve months. Balance sheet liquidity strengthened considerably.

Cash and cash equivalents were $656.9 millionc at September 30, 2024, up from $245.4 million at December 31, 2023, and the company reported no indebtedness. Net cash provided by operating activities was $418.1 million for the nine months, and no share repurchases were executed during 2024 through September 30, with $308.8 million remaining under the repurchase authorization.

Key Highlights

  1. Total revenue of $533.3 million for Q3 2024, up from $492.5 million in Q3 2023; nine-month revenue of $1.57 billion, up from $1.39 billion.
  2. Income from operations of $112.3 million for Q3 2024 versus $84.9 million a year earlier; nine-month income from operations of $321.5 million versus $249.5 million.
  3. Net income of $96.4 million, or $3.01 per diluted share, for Q3 2024, compared with $70.6 million, or $2.22 per diluted share, in Q3 2023.
  4. Backlog of $2,927.4 million as of September 30, 2024, up from $2,689.5 million a year earlier; net new business awards of $533.7 million for the quarter.
  5. Cash and cash equivalents of $656.9 million at September 30, 2024, up from $245.4 million at December 31, 2023; the company reports no indebtedness.
  6. Net cash provided by operating activities of $418.1 million for the nine months ended September 30, 2024, compared with $277.0 million in the prior-year period, driven mainly by a $111.1 million increase in advanced billings.
  7. No share repurchases in 2024 through September 30; $308.8 million remains under the $500.0 million repurchase authorization.

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$533.32M$492.50M+8.3%
SG&A Expenses$49.22M$41.41M+18.9%
Operating Expenses$421.04M$407.59M+3.3%
Operating Income$112.27M$84.91M+32.2%
Net Income$96.43M$70.55M+36.7%
EPS (Basic)$3.11$2.30+35.2%
EPS (Diluted)$3.01$2.22+35.6%
Shares Outstanding (Basic)31.05M30.63M+1.4%
Shares Outstanding (Diluted)32.09M31.76M+1.0%

Frequently Asked Questions

  1. What drove the revenue growth in the third quarter of 2024?

    The filing states that the increase in total revenue for the three months ended September 30, 2024 was primarily driven by growth within the Metabolic, Oncology and Cardiology therapeutic areas compared with the same period in the prior year.

  2. How did profitability change compared with the prior-year quarter?

    Income from operations rose to $112.3 million from $84.9 million, and net income rose to $96.4 million from $70.6 million. Diluted earnings per share were $3.01 versus $2.22. The effective tax rate was 18.8% compared with 15.2% a year earlier.

  3. What is the company's backlog and how much is expected to convert to revenue soon?

    Backlog was $2,927.4 million at September 30, 2024, compared with $2,689.5 million a year earlier. Approximately $1,610.0 million to $1,630.0 million is expected to convert to net revenue over the next twelve months, with the remainder thereafter.

  4. Why did operating cash flow and cash balances increase so much?

    Operating cash flow was $418.1 million for the nine months ended September 30, 2024, and the filing attributes the changes in operating assets and liabilities mainly to a $111.1 million increase in advanced billings. Cash also benefited from $14.6 million of proceeds from stock option exercises, and the company made no share repurchases in the period.

  5. Does the company have debt, and what is its remaining buyback capacity?

    As of September 30, 2024, the company reported no indebtedness and $10.0 million available for borrowing under its Credit Facility. It has $308.8 million remaining under its share repurchase program, which had a total authorization of up to $500.0 million.